A multiomic analysis led by the IrsiCaixa AIDS Research Institute has uncovered genetic and immune mechanisms in some ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

Researchers looked at 198 kidney transplants performed at hospitals across the United States. They found similar results ...

The availability of such kidney transplants outside of the research setting could substantially improve organ availability ...

A new study found people with HIV can safely receive donated kidneys from deceased donors with the virus. According to ...

People at risk for contracting HIV from sex can reduce their risk of infection by up to 99% when they take pre-exposure prophylaxis (PrEP), an antiretroviral medication, as directed. However ...

This week, we heard that six generic drug companies have signed voluntary licensing deals to make the HIV prevention injection ... countries not on Gilead’s list of 120. It’s an old Gilead ...

Combine PEPFAR and the Global Fund into one country-level national HIV commission, and combine the procurement systems for medications, laboratory testing and reporting. Monitor HIV and TB ...

Lenacapavir is an important medication for HIV prevention and treatment. The agreement aims to bolster access to lenacapavir in 120 countries, with a particular focus on resource-limited nations that ...

welcomed US-based Gilead Science's announcement of voluntary licensing of its long acting HIV drug lenacapavir for generic production, and asked the company to announce the specific prices of the drug ...

Gilead Sciences GILD has entered into licensing deals with six pharmaceutical companies to manufacture and supply a cheaper version of its investigational drug, lenacapavir, for HIV prevention ...